bone marrow depots
BMC via IV Therapy

Considerations On the Regulatory Status of IV Administration of BMC: A Useful Shot in the Arm? Part Three

Over the previous couple of posts, I have been reviewing the love/hate relationship the FDA seems to have with therapy provided by an IV route. They issued a blanket determination in the MM/HU Guidance that IV therapies of HCT/Ps would be considered risky and therefore physicians offering IV therapies of HCT/Ps would be more rapidly...
Read More
Bone Marrow-Derived Cells

Combination Cell-Based Therapies: A Very Sparse Record Except for Combo-Fat Grafting with Bone Marrow – Part Two

In the last post, I had finished covering the experimental design and describing the fluids Xing, et al. used in a study of the influence of bone marrow-derived fluid to augment fat graft survival in the rabbit. I will continue in this post with a review of the results they reported. Refer to Part One...
Read More
Bone Marrow and MSCs Through the Ages

Hernigou and Bone Marrow-Derived MSCs Through the Ages

There are a lot of folks going around saying that you suffer a dramatic loss of bone marrow stem cells (the mesenchymal stem cell [MSC] version) from your body’s bone marrow depots as you age. Which is true to a certain extent, but, as usual, the devil is in the details. Some of those who...
Read More
Health of Bone Marrow Depots

The Dynamics of Healthy Bone Marrow Depots

One theme of the last few posts on Dr. Philippe Hernigou’s pioneering use of BMC to treat soft and bony tissue pathologies has been the need to boost the bone marrow cellularity and/or its vitality. What? You haven’t caught on that the real objective of treating orthopedic pathologies is to make sure the adjacent bone...
Read More